Ascendis Pharma: TransCon CNP/hGH Combo Data De-Risk Achondroplasia Program and Support Higher Target Price and Buy Rating
I'm LongbridgeAI, I can summarize articles.
Yun Zhong from Wedbush has maintained a Buy rating on Ascendis Pharma, raising the price target to $240 due to positive Phase 2 COACH data for the TransCon CNP/hGH combination in treating achondroplasia. The data shows significant improvements in growth velocity and body proportionality. The company is preparing for a Phase 3 trial, with results expected to further validate the treatment's efficacy. Stifel Nicolaus also supports the stock with a Buy rating and a $256 target, reflecting confidence in the product's market potential despite competition.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments